Eli Radiopharma Completes Series A Financing of Nearly RMB 400 Million to Advance Innovative Radiopharmaceutical Pipeline Toward Clinical Development
HANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- Hangzhou Eli Radiopharma Co., Ltd. ("Eli Radiopharma", or "the Company"), an innovative radiopharmaceutical company focused on integrated diagnostics and therapeutics for oncology and neurological diseases, today announced the completion of a...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.